Breadcrumb

[A18-41] Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2018-06-21 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Executive summary of dossier assessment  [PDF, 127 kB] (German version) Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A18-76] Pertuzumab (breast cancer) - Addendum to Commission A18-41
Status: Commission completed

[A16-01] Pertuzumab - Addendum to Commission A15-34
Status: Commission completed

[A15-34] Pertuzumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed

[A13-28] Addendum to Commission A13-10 (pertuzumab)
Status: Commission completed

[A13-10] Pertuzumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2018-10-01 Executive summary of dossier assessment (German version) 127 kBPDFdownload file
2018-10-01 Dossier assessment (German version) 2 MBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Federal Joint Committee (G-BA)

2018-12-20 A G-BA decision was published.

G-BA documents on this decision

Press releases

2018-10-01 Pertuzumab in early breast cancer: no added benefit proven despite exemplary surrogate validation



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close